Hemolytic Uremic Syndrome with Clopidogrel after Coronary Angioplasty.
- Author:
Si Hyung PARK
1
;
Jin Han PARK
;
Sang Yool PARK
;
Eun Ji LEE
;
Hyun Soo JUN
;
Yeong Hoon KIM
;
Yang Wook KIM
Author Information
1. Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
- Publication Type:Case Report
- Keywords:
Clopidogrel;
Hemolytic uremic syndrome
- MeSH:
Acute Coronary Syndrome;
Acute Kidney Injury;
Anemia, Hemolytic;
Angioplasty;
Dyspnea;
Edema;
Hemolytic-Uremic Syndrome;
Humans;
Incidence;
Korea;
Middle Aged;
Peripheral Arterial Disease;
Plasma Exchange;
Platelet Aggregation Inhibitors;
Stents;
Stroke;
Thienopyridines;
Thrombocytopenia;
Thrombosis;
Ticlopidine
- From:Korean Journal of Medicine
2011;80(Suppl 2):S253-S257
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Thienopyridines are antiplatelet agents used in post-percutaneous coronary angioplasty patients and patients with acute coronary syndrome, stroke, and peripheral arterial disease. Ticlopidine has been shown to reduce the incidence of stent thrombosis, but it may also cause serious hematological side effects. Among the thienopyridines, clopidogrel is considered to be a safe alternative to ticlopidine because of its decreased incidence of hematological adverse effects. However, some hematological side effects can occur and may be fatal. In this case, a 47-year-old man complained of dyspnea and generalized edema. He had been taking clopidogrel after coronary angioplasty. His laboratory findings showed acute renal failure, microangiopathic hemolytic anemia, and thrombocytopenia, which were consistent with hemolytic uremic syndrome (HUS). After discontinuing clopidogrel and undergoing plasma exchange, he recovered fully. To our knowledge, this is the first reported case of clopidogrel-induced HUS in Korea.
